Business Context and Reporting Period
Company: INNOVATE Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2022
Reporting Period Referenced: Third Quarter ended September 30, 2022 (results announced November 2, 2022).
Key Financial Metrics
This filing serves as a notice of events and does not contain specific financial data points. The text references an attached Earnings Release (Exhibit 99.1) and Investor Presentation (Exhibit 99.2) for detailed results.
- Revenue, Profit, Cash Flow, Margins: Not provided in this filing text.
- Debt and Liquidity: Not provided in this filing text.
- Share Price: The average closing price of Common Stock was less than $1.00 per share over a consecutive 30 trading-day period.
Material Changes and Listing Status
NYSE Delisting Notice: On October 27, 2022, the Company received a written notice from the New York Stock Exchange (NYSE) stating it was not in compliance with Section 802.01C of the Listed Company Manual due to the share price falling below $1.00.
- Immediate Impact: No immediate impact on listing status; the stock remains listed subject to other requirements.
- Cure Period: The Company has six months from the receipt of the notice to regain compliance.
- Compliance Requirement: To regain compliance, the Common Stock must have a closing price of at least $1.00 and an average closing price of at least $1.00 over a 30 trading-day period ending on the last trading day of any calendar month within the cure period.
- Consequence of Failure: If compliance is not achieved within the six-month period, the NYSE will initiate procedures to suspend and delist the Common Stock.
Guidance, Outlook, and Management Commentary
Management Action: The Company plans to notify the NYSE of its intent to regain compliance and is considering all available options in the best interests of the Company and its shareholders.
Investor Communication: A conference call was scheduled for November 2, 2022, at 4:30 p.m. ET to discuss the Third Quarter 2022 results. Presentation slides were made available on the Company's Investor Relations website.
Risks and Contingencies: The primary risk identified is the potential delisting from the NYSE if the minimum share price requirement is not met within the six-month cure period.
Investor Verification Checklist
- Verify the specific revenue, profit, and cash flow figures in the attached Earnings Release (Exhibit 99.1).
- Review the Third Quarter 2022 Conference Call Investor Presentation (Exhibit 99.2) for management's detailed strategy to address the share price decline.
- Monitor the Company's stock price daily to track progress toward the $1.00 minimum threshold required for NYSE compliance.
- Confirm the Company's specific plan to regain compliance (e.g., reverse stock split, operational improvements) as it is currently stated only as "considering all available options."